Internal Reference Number: FOI_9655
Date Request Received: 18/09/2026 00:00:00
Date Request Replied To: 28/09/2026 00:00:00
This response was sent via: By Email
Request Summary: Multiple Sclerosis
Request Category: Researcher
| Question Number 1: How many patients received treatment for any condition in the last six months with any of the following treatment regimens (March 2026 鈥� August 2026)? 鈥� Ocrevus (ocrelizumab) IV 鈥� Ocrevus (ocrelizumab) Subcutaneous 鈥� Kesimpta (ofatumumab) 鈥� Briumvi (ublituximab) 鈥� Mavenclad (cladribine) 鈥� Dimethyl Fumarate (Tecfidera + Dimethyl Fumarate generic) 鈥� Vumerity (diroximel fumarate) 鈥� Tysabri (natalizumab) IV 鈥� Tysabri (natalizumab) Subcutaneous 鈥� Tyruko (natalizumab biosimilar) 鈥� Any Other Platform Therapies (interferon Beta, peginterferon beta-1a, teriflunomide, glatiramoids) 鈥� S1P Receptor Modulators (fingolimod, siponimod, ponesimod, ozanimod) 1a. Of the patients identified in question one, how many of the same patients received treatment with each treatment regimen in November 2025-April 2026 AND March 2026 鈥� August 2026)? 鈥� Ocrevus (ocrelizumab) IV 鈥� Ocrevus (ocrelizumab) Subcutaneous 鈥� Kesimpta (ofatumumab) 鈥� Briumvi (ublituximab) 鈥� Mavenclad (cladribine) 鈥� Dimethyl Fumarate (Tecfidera + Dimethyl Fumarate generic) 鈥� Vumerity (diroximel fumarate) 鈥� Tysabri (natalizumab) IV 鈥� Tysabri (natalizumab) Subcutaneous 鈥� Tyruko (natalizumab biosimilar) 鈥� Any Other Platform Therapies (interferon Beta, peginterferon beta-1a, teriflunomide, glatiramoids) 鈥� S1P Receptor Modulators (fingolimod, siponimod, ponesimod, ozanimod) | |
| Answer To Question 1: Please see our response to all questions in the Excel spreadsheet attached. To accompany this answer to question 1 please also see the documents listed below:  13985 - FOI_9655 - Multiple Sclerosis.xlsx | |
| Question Number 2: How many patients have received a new diagnosis for Multiple Sclerosis in the latest six-month period (March 2026 鈥� August 2026)? 2a. Of the patients identified in question two, how many of these patients have received any of the following treatment regimens as their first treatment following their Multiple Sclerosis diagnosis? 鈥� Ocrevus (ocrelizumab) IV 鈥� Ocrevus (ocrelizumab) Subcutaneous 鈥� Kesimpta (ofatumumab) 鈥� Briumvi (ublituximab) 鈥� Mavenclad (cladribine) 鈥� Dimethyl Fumarate (Tecfidera + Dimethyl Fumarate generic) 鈥� Vumerity (diroximel fumarate) 鈥� Tysabri (natalizumab) IV 鈥� Tysabri (natalizumab) Subcutaneous 鈥� Tyruko (natalizumab biosimilar) 鈥� Any Other Platform Therapies (interferon Beta, peginterferon beta-1a, teriflunomide, glatiramoids) 鈥� S1P Receptor Modulators (fingolimod, siponimod, ponesimod, ozanimod) | |
| Answer To Question 2: Please see our response to all questions in the Excel spreadsheet attached. | |
| Please see Attachments: | |
| To return to the list of all the FOI requests please click here | |
Our staff at 麻豆国产 District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
